This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Clinical Trial Dates

On a less positive note, Insmed (INSM) shares dropped from $2.33 to $1.08 after the company released negative results from a phase II study of its drug iPlex in muscular dystrophy. The stock was most recently trading at $1.09.

Now, the new clinical trials list:

Company: Myriad Pharmaceuticals (MYRXV)
Drug/indication: Azixa for cancer
Clinical trial event: Phase II results in brain cancer and metastatic melanoma
Timing: 2009

Myriad Pharmaceuticals is a new company focused on drug discovery and development that was spun out of genetics diagnostics maker Myriad Genetics (MYGN - Get Report). The first test of strength for Myriad Pharmaceuticals' pipeline will come from the results of the phase II Azixa studies.

Company: Onyx Pharmaceuticals (ONXX)
Drug/indication: Nexavar for breast cancer
Clinical trial event: Phase II study results
Timing: 2009

Onyx believes Nexavar has more utility in cancer than just its current approvals for liver and kidney cancers. Two phase II studies in breast cancer patients that combine Nexavar with the chemotherapy drugs gemcitabine and paclitaxel, respectively, will help determine whether Nexavar's market potential can be expanded.

Company: Optimer Pharmaceuticals (OPTR)
Drug/indication: Fidaxomicin (OPT-80) for clostridium difficile infection
Clinical trial event: Phase III results
Timing: Fourth quarter 2009

In the first phase III study last year, fidaxomicin outperformed vancomycin, the current standard of care for patients infected with the clostridium difficile bacteria. Optimer is hoping that the second phase III study yields the same positive results, which will allow the company to seek the drug's marketing approval.

Company: Osiris Therapeutics ( OSIR)
Drug/indication: Prochymal for graft-vs.-host disease
Clinical trial event: Phase III results
Timing: Fourth quarter

I must acknowledge a negative bias with respect to Osiris because the stock was a short recommendation in my model portfolio. The reason is simple: I don't believe in the efficacy of Prochymal, a concoction derived from mesenchymal stem cells. Failed Prochymal studies in lung disease and Crohn's disease lend credence to my skepticism, I believe, but the ultimate judgment on Prochymal will come when data from two phase III studies in graft-vs.-host disease are released.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
CELG $103.22 -1.67%
INSM $11.74 -5.70%
JAZZ $152.47 -0.07%
MYGN $36.19 -1.28%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs